R. Stupp

Discipline

Psychologie (13) Histoire, Philosophie et Sociologie des sciences (2) Economies et finances (2) Sciences de l'information et de la communication (1)

Type de document

Articles (52) Recensions (14) Colloques et conférences (2)

Co-auteur

Date

Source

Mot-clé

Treatment (42) Patients (38) Patients (38) Human beings (36) survie (34) Survival (34) Brain (27) cerveau (27) Chemotherapy (26) Chemotherapy (25) procès (24) Tumors (24) thérapie (21) Therapeutics (21) Cancer (21) Older people (21) Radiotherapy (20) adulte (19) Months (19) Use (19) Radiotherapy (19) adulte (19) analyse (18) Methods (18) Methods (18) Analysis (18) norme (16) cancer (16) Cancer (16) maladie (14)

Documents écrit par R. Stupp (54) | parle de R. Stupp (0)

Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14.
D. König et al. (11 juil. 2023)
DNA methylation-based age acceleration observed in IDH wild-type glioblastoma is associated with better outcome-including in elderly patients.
P. Bady et al. (24 mars 2022)
Memory in low-grade glioma patients treated with radiotherapy or temozolomide: a correlative analysis of EORTC study 22033-26033.
M. Klein et al. (5 mai 2021)
MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials.
M.E. Hegi et al. (15 mars 2019)
The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033.
P. Bady et al.
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
R. Stupp et al. (19 déc. 2017)
European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas.
M. Weller et al.
Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082).
W. Wick et al. (1 oct. 2016)
Tumor treating fields: a novel treatment modality and its use in brain tumors.
A.F. Hottinger et al.
Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome.
M. Weller et al. (22 mars 2016)
Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.
B.G. Baumert et al. (2016)
Withholding temozolomide in glioblastoma patients with unmethylated MGMT promoter--still a dilemma?
M.E. Hegi et al. (2015)
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
R. Stupp et al. (2015)
Chromosome 7 gain and DNA hypermethylation at the HOXA10 locus are associated with expression of a stem cell related HOX-signature in glioblastoma.
S. Kurscheid et al. (2015)
Genome-wide DNA methylation detection by MethylCap-seq and Infinium HumanMethylation450 BeadChips: an independent large-scale comparison.
T. De Meyer et al. (2015)
Standards of care and novel approaches in the management of glioblastoma multiforme.
A.F. Hottinger et al. (2014)
T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein.
J. Laurent et al. (2013)
A phase 1b study of humanized KS-interleukin-2 (huKS-IL2) immunocytokine with cyclophosphamide in patients with EpCAM-positive advanced solid tumors.
J.P. Connor et al. (2013)
Erratum to: MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status.
P. Bady et al. (2013)
Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial.
M.E. Hegi et al. (2012)
MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status.
P. Bady et al. (2012)
Decision making and management of gliomas: practical considerations.
A.F. Hottinger et al. (2012)
Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group.
R. Stupp et al. (2011)
Minimal clinically meaningful differences for the EORTC QLQ-C30 and EORTC QLQ-BN20 scales in brain cancer patients.
J. Maringwa et al. (2011)
Targeting integrins in malignant glioma.
G. Tabatabai et al. (2010)

next